Argent BioPharma Limited (MGCLF)

0.2600 0.0000 (0.00%) At close: 10:34AM EDT

Argent BioPharma Limited

295 Rokeby Road
Suite 1
Subiaco, WA 6008
Australia
61 8 6555 2950
https://mgcpharma.com.au

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Roby Reuven Zomer	Co-Founder, CEO, MD & Executive Director	232.82k	N/A	1980
Mr. Tom Cairns	Chief Accounting Officer	N/A	N/A	N/A
Ms. Yifat Steuer	Deputy CEO & COO	N/A	N/A	N/A
Ms. Nicole Ann Godresse	Global Chief Sales Officer	N/A	N/A	N/A
Mr. Amir Polak	Chief Pharmaceutical Development Officer	N/A	N/A	N/A
Ms. Sabina Suljakovic	Head of the Quality Assurance Department	N/A	N/A	N/A
Dr. Nadya Lisovoder	Chief Medical Officer	N/A	N/A	N/A
Ms. Sasha Friedman	Deputy CEO	N/A	N/A	N/A
Yair Tal	Chief Information Security Officer	N/A	N/A	N/A
Mr. Robert Clements	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer. The company was formerly known as MGC Pharmaceuticals Limited and changed it name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Corporate governance

Argent BioPharma Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.